NASDAQ: VSTM

China-based GenFleet Therapeutics has entered into an exclusive licensing and early development agreement with US firm Verastem Oncology (NASDAQ: VSTM). Under the agreement, Verastem will obtain development and commercialization rights to GenFleet’s three oncology discovery programs targeting RAS pathway-driven cancers, excluding Greater China. Financial Terms and Potential Deal SizeThe agreement…